Creutzfeldt-Jakob Disease and blood/plasma supply to be topic of FDA conference in early 1996.
Executive Summary
FDA, BLOOD PRODUCTS ASSOCIATIONS PLANNING EARLY 1996 CJD CONFERENCE, American Red Cross Senior Principal Officer Blood Services North Atlantic Area Peter Page, MD, indicated during the Dec. 14 session of FDA's Blood Products Advisory Committee. The committee heard an update from the agency and industry regarding procedures for handling blood and plasma product from donors at risk for or later diagnosed with Creutzfeldt-Jakob Disease, a rare spongiform encephalopathy.